The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Targeting A Bacterial Glyco-Achilles Heel To Make New Vaccines For Haemophilus Influenzae And Neisseria Gonorrhoeae.
Funder
National Health and Medical Research Council
Funding Amount
$526,950.00
Summary
The bacteria that cause gonorrhoea (N. gonorrhoeae), middle ear infections and exacerbations of chronic obstructive lung disease (H. influenzae) have become multi-drug resistant. These diseases are a major health and economic burden. In the absence of new drugs, a vaccine to prevent these diseases has emerged as a major unmet need in human health. In this grant, we will develop a new vaccine that targets a bacterial-specific sugar that we have discovered is the Achilles heel of these bacteria.
Strain-level Characterisation And Visualisation Of The Mucosal Microbial Communities Associated With Inflammatory Bowel Disease (IBD) For The Development Of Novel Biotherapeutics
Funder
National Health and Medical Research Council
Funding Amount
$1,181,878.00
Summary
Australia has one of the highest incidence rates in the world of Inflammatory Bowel Disease (IBD), a debilitating inflammatory condition of the gastrointestinal tract. Cutting-edge molecular and visualisation technologies will be used to examine the role of the gut microbiome in IBD, and identify specific members of this community to be used as new therapies to suppress inflammation and improve outcomes for patients with IBD.